The TOPS study randomized patients 2:1 to receive either 800 mg/day or 400 mg/day imatinib. However, at 12 months the authors could not detect a statistically significant difference in MMR (46 vs ...

Up to 85% of patients treated with 400 mg imatinib achieve a complete cytogenetic response (CCR) and 40–60% achieve a major molecular response (MMR). These responses are stable in many patients ...

Through chemical changes, the binding affinity for ABL was improved compared with imatinib, making nilotinib ... blastic phase in both nilotinib arms (400 mg twice daily or 300 mg twice daily ...

This 5-arm study randomized 1,241 patients to receive either 400 mg imatinib, 800 mg imatinib, 400 mg imatinib and interferon, 400 mg imatinib and cytarabine, or 400 mg imatinib after failure ...